The shareholders of Qlucore AB (publ), reg. no. 556719-3528 (“Company”) are hereby convened to an extraordinary general meeting on Wednesday 16 February 2022 at 10.00 AM at Qlucore’s office at Scheelevägen 17 1TR, 222 63 Lund.

Notification etc.
Shareholders wishing to participate in the general meeting shall:

  • partly, be entered in the shareholders’ register kept by Euroclear Sweden AB on the record day Tuesday 8 February 2022.
  • partly, register their participation so that it is received by the Company no later than Tuesday 15 February 2022 to the address c/o Carl-Johan Ivarsson, Scheelevägen 17 1TR, 223 63 Lund or via e-mail to carl-johan.ivarsson@qlucore.com. When registering, the shareholder’s name, personal or organization number (or equivalent) and preferably an address, telephone number (daytime), shareholding information on any assistants (maximum two), and, where applicable, information on deputies or representatives.

Proxy

  • Shareholders who are represented by a proxy must issue a written power of attorney for the proxy. The person representing a legal person must present a registration certificate (or equivalent authorization document) which shows that the persons who have signed the power of attorney (with any authorization documents) should be sent to the company together with the notification of participation. The period of validity of the power of attorney may be specified for a maximum of one year from the date of issue.

Nominee-registered shares

  • Shareholders who have had their shares registered with a nominee must, in order to be entitled to participate in the general meeting, temporarily register the shares in their own name in the share register kept by Euroclear Sweden AB as of the record date as described above. Shareholders who wish to register their shares in their own name must, in accordance with the respective nominee’s routines, request that the nominee make such registration. Registration of voting rights that has been requested by shareholders at such a time that the registration has been made by the nominee no later than Tuesday 8 February 2022 will be taken into account in the production of the share register.

Items at the meeting

  1. Opening of the general meeting and election of chairman of the meeting
  2. Preparation and approval of the voting register
  3. Election of one or two persons to verify the minutes
  4. Approval of the agenda
  5. Determination as to whether the general meeting has been duly convened
  6. Determination of the number of members of the board
  7. Election of a new member of the board
  8. Closing of the general meeting

Item 1 – Election of chairman of the meeting
It is proposed that Thoas Fioretos is elected chairman of the general meeting, or in his absence, the one the board appoints.

Item 6 – Determination of the number of members of the board
It is proposed that the number of board members, for the period until the end of the next Annual General Meeting, shall consist of seven board members and no deputies.

Item 7 – Election of a new member of the board
It is proposed, for the period until the end of the next Annual General Meeting, that Helle Fisker is newly appointed as regular member of the board.

Helle Fisker, M Sc in Biotechnology and executive MBA has more than 20 years of experience in senior sales and marketing roles in the fields of Medtech and Biotech. She has extensive commercial experience from taking to the global market more than 300 tests for cancer diagnostics, applications for digital Pathology, as well as Oncology treatments and vaccines in Denmark. Helle Fisker works as VP Commercialization for Biovica and is the founder of her own consulting company – BioBrandAware. Helle Fisker is independent in relation to the Company and to the Company’s major shareholders.
If the General Meeting resolves in accordance with the proposal, the Board of Directors will consist of Carl-Johan Ivarsson, Pia Gideon, Boel Sundvall, Thoas Fioretos, Magnus Fontes, Johan Thiel and Helle Fisker.

Shareholders’ right to request information
The Board of Directors and the Managing Director shall, if any shareholder so requests and the Board considers that this can be done without significant harm to the Company, provide information on circumstances that that may affect the assessment of a matter on the agenda, circumstances that may affect the assessment of the Company’s or subsidary’s financial situation and the Company’s relationship with another group company. Such a request from shareholders must be submitted in writing to the company no later than ten days before the general meeting by post to the address Qlucore AB, ref: Carl-Johan Ivarsson, Scheelevägen 17 1TR, 223 63 Lund (Mark the letter “Extraordinary General Meeting”) or by e-mail to the address carl-johan.ivarsson@qlucore.com. The information will be available on the Company’s website www.qlucore.com and at the Company’s office at Qlucore AB, Scheelevägen 17 1TR, 223 63 Lund no later than five days before the meeting. The information is also sent to the shareholder who requested it and provided their address.

Provision of documents
A complete set of proposals for the resolutions, and, where applicable, reasoned opinions as well as other documents pursuant to the Swedish Companies Act will be available from the Company’s office with address Qlucore AB, Scheelevägen 17 1TR, 223 63 Lund and on the Company’s website, www.qlucore.com, not later than two weeks before the meeting. Copies of the documents are sent to shareholders who have requested this and provided their postal address free of charge.

Processing of personal data
For information on how personal data is processed in connection with the general meeting, please refer to the privacy policy available on Euroclear Sweden AB’s website, https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.

Lund in January 2022
Qlucore AB (publ)
The Board of Directors

© Modular Finance, source Nordic Press Releases